drugset / Trial / NCT07357649

Baricitinib Effects on Procoagulant State in Rheumatoid Arthritis

NCT07357649

Phase 4 Not yet recruiting 100 enrolled Tanta University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This prospective interventional study aims to evaluate the effects of baricitinib on disease activity, lipid profile, atherogenic index, and procoagulant biomarkers including monocyte-derived human tissue factor and D-dimer in patients with rheumatoid arthritis, compared with conventional therapy.

Timeline

Start
2026-01
Primary completion
2026-04
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Baricitinib Small molecule Oral
Background Methotrexate Small molecule

Indications